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Innate immunitytiated by a profound loss of CD4+ T-cells is fundamental to HIV-induced
pathogenesis. Infection of domestic cats with a non-pathogenic lentivirus prevalent in the puma (puma
lentivirus, PLV or FIVPCO) prevented peripheral blood CD4+ T-cell depletion caused by subsequent virulent FIV
infection. Maintenance of this critical population was not associated with a signiﬁcant decrease in FIV
viremia, lending support to the hypothesis that direct viral cytopathic effect is not the primary cause of
immunodeﬁciency. Although this approach was analogous to immunization with a modiﬁed live vaccine,
correlates of immunity such as a serum-neutralizing antibody or virus-speciﬁc T-cell proliferative response
were not found in protected animals. Differences in cytokine transcription proﬁle, most notably in interferon
gamma, were observed between the protected and unprotected groups. These data provide support for the
importance of non-adaptive enhancement of the immune response in the prevention of CD4+ T-cell loss.
© 2008 Elsevier Inc. All rights reserved.Introduction
Dysregulation of the immune response brought on by the loss of
CD4+ T-cells is the initiator of progression to Acquired Immunodeﬁ-
ciency Syndrome (AIDS) following infection with human immunode-
ﬁciency virus (HIV) (Alimonti et al., 2003; Douek et al., 2003; Lackner
and Veazy, 2007), virulent simian immunodeﬁciency virus (SIV)
infection in Asian macaques (Lackner and Veazy, 2007; Viollet et al.,
2006) and virulent feline immunodeﬁciency virus (FIV) infection in
domestic cats (Bendinelli et al., 1995; Egberink and Horzinek, 1992).
Prevention of CD4+ T-cell loss following HIV infection has not been
achieved despite more than 20-years of vaccine research, although
multi-drug therapy has proven successful in extending patient survival
(Lima et al., 2007; Rogers et al., 2000). Reduction in viral load or
preservation of CD4+ T-cells has been noted in a small percentage oft of Microbiology, Immunology
edical Sciences, Colorado State
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l rights reserved.animals in individual vaccine studies using SIV or simian/human virus
hybrids in non-human primate models (Ahmed et al., 2002; Connor
et al., 1998; Stolte-Leeb et al., 2006). Due in part to this variation in
response thesemodels have not yet revealed an obvious approach or an
immune response to target in order to prevent infection or the
development of AIDS (Davenport et al., 2007; Douek et al., 2003;
Lackner and Veazy, 2007; McMichael, 2006). Further, the cause of the
CD4+ T-cell depletion during HIV infection is controversial (Alimonti
et al., 2003; Hel et al., 2006). Viral infection can directly cause the death
of these cells (Alimonti et al., 2003); however following recognition that
the rate of cell death far exceeds the infection rate, it has been
postulated that the chronic nature of the immune response and
induction of apoptosis in activated bystander cells are at least in part
responsible for the disease state resulting from virulent HIV and SIV
infections (Anderson et al., 1998; Douek et al., 2003; Hel et al., 2006),
recently it has been recognized that even the chronic state of activation
maynot explain the kinetics of CD4+T-Cell depletion (Yates et al., 2007).
FIV infection has many analogies to HIV infection; the virus
has emerged relatively recently, targets similar cell types, and the
disease state demonstrates a similar time course, clinical signs and
outcome (Bendinelli et al., 1995; Overbaugh et al., 1997; Siebelink
et al., 1990). Concurrently, FIVs which are endemic to the non-
domestic cat population parallel SIVagm and other naturally occurring
SIVs in that they are minimally pathogenic in their natural host
(VandeWoude and Apetrei, 2006). Our previous work indicates that
infection of domestic cats with a lentivirus native to the puma (FIVPCO
Fig. 1. Mean PLV viral copy number per 1 million PBMCs as measured by real time PCR in
groups inoculatedwith PLV ormediumonly on day 0. Bars indicate the standard deviation.
Five animalswere inoculatedwith FIV onday 28.N=10 for days 3,10,17 and24 andn=5 for
day 31 and thereafter. A number less than 5 above the standard deviation bar indicates the
numberof animals thathad copynumbers above the lower limitofdetection.Calculationof
means used values for only those animals with detectable virus.
Fig. 2.Mean CD4-positive T-Cell counts in groups inoculated with PLV or medium only
on day 0. Solid diamonds represent the PLV-inoculated group and open boxes represent
the medium-inoculated controls. Arrow indicates inoculation of 5 animals from each
group with FIV or diluent. Solid triangles represent the single-virus inoculated group
(FIV only) and shaded circles represent the dual-virus inoculated group. Asterisks
indicate a statistically signiﬁcant difference (p≤0.05) from baseline values.
Fig. 3. FIV copy number per 1 million PBMCs (A) and FIV copy number per milliliter of
plasma (B) as measured by PCR in individual animals inoculated with PLV on day 0
followed by FIV on day 28 (shaded circles) or medium only on day 0 followed by FIV on
day 28 (solid triangles). Asterisk indicate the single time point at which the higher copy
number in the FIV-only group were statistically signiﬁcantly higher than in the group
inoculated with PLV prior to FIV.
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lymphadenopathy and only a slight, transient decrease in CD4+ T-cell
count. PBMC viral burden gradually decreases over the course of
several months of infection and is ultimately virtually eliminated by
the host without evidence of strong adaptive immune activation.
In late infection, proviral burden persisted in gastrointestinal vs
lymphoid compartments (TerWee et al., 2005). In this study, domestic
cats were inoculated with PLV or sham inoculum (n=10/group). After
infection was established, ﬁve animals from each group were
inoculated with virulent FIV and monitored for clinical signs,
peripheral blood cell counts, CD4+ and CD8+ T-Cell counts, cellular
and plasma viral loads, humoral and cellular immune response, and
PBMC cytokine expression. A highly pathogenic molecular clone of FIV
subtype C which induces high viral loads and signiﬁcant CD4+ T-Cell
loss early after infection (De Rozières et al., 2004) was used as the
challenge virus. Protection against CD4+ T-cell depletion was afforded
by prior infectionwith a non-pathogenic lentivirus using the domestic
cat model of immunodeﬁciency virus pathogenesis.
Results
PLV infection was uniformly detected by 3 days post inoculation
Fig. 1 demonstrates mean viral copy number in peripheral blood
mononuclear cells (PBMC) from cats inoculated with PLV on day 0 as
assessed by real time PCR speciﬁc for PLV-1695. Provirus was detected
in all PLV-inoculated cats by 3 days after inoculation, while virus was
not detected in sham-inoculated controls or animals only infected
with FIV at any time point. Copy number peaked at an average of
1 copy per 500 cells at day 10 and then declined, becoming no longer
regularly detectable in some individual animals beyond day 37.
Cellular virus was still detectable in 4 animals at levels of 1 copy per
1000 cells to 1 copy per 100,000 cells at the last time point (day 108).
Prior PLV infection rescued CD4+ T-cell depletion following virulent FIV
infection
Complete white blood cell counts with differentials were con-
ducted to determine if the kinetics of CD4+ T-Cell depletion in FIV-C
infection was altered by prior PLV infection. As shown in Fig. 2 and
consistent with previous observations, CD4+ T-cell count was not
signiﬁcantly decreased by infection with PLV (study days 10, 17 and
24) and in fact there was a signiﬁcant increase in CD4+ T-cell count in
PLV-only inoculated animals at day 31. Lymphocyte and white blood
cell (data not shown) counts were also unchanged following PLVinoculation. One-half of the PLV-infected animals and one-half of the
sham-inoculated controls were inoculated with FIV on day 28
(indicated by an arrow). The PLV-negative, FIV-inoculated cats (solid
triangle) demonstrated a marked decline in CD4+ T-cell count by
3 days after FIV inoculation which persisted for the course of the
study. The differences attained statistical signiﬁcance on days 3, 9, 17,
31, 38 and 66 post FIV (study days 31, 37, 45, 59, 66 and 94). This
decline in CD4+ T-cell count was reﬂected in total lymphocyte count
with a statistically signiﬁcant decrease on days 31, 37, 45, 52 and 59
Fig. 4. Serum Neutralizing Antibody (SN) titer measured 59 days post PLV inoculation in
individual animals inoculated with PLV on day 0 followed by FIV on day 28 (circles),
medium only on day 0 followed by FIV on day 28 (triangles), PLV on day 0 followed by
0.9% NaCl on day 28 (diamonds) or medium only on day 0 followed by 0.9% NaCl on day
28 (squares). There was no statistically signiﬁcant difference between groups.
Fig. 5. Lymphocyte blastogenesis response to mitogen or antigen as measured by
incorporation of 3H thymidine. PBMCs were stimulated in triplicate with 1 µg of
inactivated PLV or FIV for 4 days or with 1.5 µg Con A for 3 or 4 days prior to incubation
in the presence of 3H thymidine and harvest. Stimulation indices (SI) were calculated by
dividing the average count for each agent by that of the average count for unstimulated
cells. Groupmean SI are shown for A) mitogen B) PLV or C) FIV in groups inoculatedwith
PLV or medium only on day 0. Solid diamonds represent the PLV-inoculated group and
open boxes represent the medium-inoculated controls. Five animals were inoculated
with FIV or diluent on day 28. Solid triangles represent the single-virus inoculated
group (FIV only) and shaded circles represent the dual-virus inoculated (PLV followed
by FIV) group. As indicated by an asterisk, the only statistically signiﬁcant differencewas
in Con A response on Day 59 in the PLV-only group (SI of 23) was compared to the
control group (SI of 5).
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(solid gray circles) showed a statistically signiﬁcant decline in CD4+
T-cell count only at day 37 (9 days post FIV inoculation) and a
decrease in lymphocyte count on days 37 and 45. Control animals
also demonstrated a statistically signiﬁcant increase in CD4+ T-cell
count on study day 52. White blood cell count (data not shown) was
signiﬁcantly higher in PLV-only infected animals on study days 31
and 52, signiﬁcantly lower in FIV-infected animals on study days 37,
59 and 66 and signiﬁcantly lower in dual-infected animals on study
days 59, 66 and 94. In summary, PLV infection did not result in CD4+
T-Cell depletion, and prevented the sustained loss brought about by
FIV-C infection in all animals.
FIV PBMC proviral load is slightly diminished in cats previously inoculated
with PLV
FIV-C in PBMCs and in plasma was measured by real time PCR to
determine if prior PLV infection inhibited FIV infection. FIV was not
detected in either group at day 31 (3 days after FIV inoculation).
However, as shown in Fig. 3A, both PLV and sham-inoculated controls
had a similar FIV copy number in PBMCs on day 37 (9 days after
inoculation). FIV viral copy number in PBMCs was statistically sig-
niﬁcantly lower in PLV-inoculated animals only on study day 52.
However there was a trend for FIV copy number to be lower in PLV-
inoculated animals throughout the study, with p values of 0.071 and
0.100 on study days 45 and 66 respectively. FIV plasma viremia was
measured on study days 37, 59 and 80. As shown in Fig. 3B, these
results support the lack of overall reduction in FIV replication by
previous PLV infection as there were no signiﬁcant differences
between the two groups at the time points examined. Sham inoculated
animals, and those only infectedwith PLV,were FIV negative at all time
points when evaluated by real time PCR (data not shown).
Protection from CD4 depletion does not correlate with acquired immunity
To determine if prior infection with PLV primed an antibody or
T-Cell response to FIV, we examined SN antibody 3 weeks after
FIV inoculation. As shown in Fig. 4, FIV SN antibody titer at day 59
(day 31 post FIV) was not signiﬁcantly different in cats inoculated
with FIV compared to those infected with PLV prior to FIV, in-
dicating no anamnestic response to FIV following PLV infection.
FIV SN titer ranged from 1:5 to 1:70 in PLV-infected animals
and 1:3 to 1:20 in FIV-infected animals. Only 1 PLV single-virus-
inoculated animal had a detectable SN response to FIV.
Fig. 7.Mean neutrophil counts in groups inoculated with PLV or medium only on day 0.
Solid diamonds represent the PLV-inoculated group and open boxes represent the
medium-inoculated controls. Arrow indicates inoculation of 5 animals from each group
with FIV or diluent. Solid triangles represent the single-virus inoculated group (FIV only)
and shaded circles represent the dual-virus inoculated (PLV followed by FIV) group.
Asterisks indicate a statistically signiﬁcant difference (p≤0.05) from baseline value.
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determined at various study time points (Fig. 5). Although the group
infected with FIV had the lowest Concanavalin A (Con A) response at
most time points, there were no statistical differences as compared to
controls in response in any group in proliferation to Con A (study days
−4, 17, 31, 45 and 66). The group inoculated with FIV following PLV
infection had a signiﬁcantly higher Con A response as compared to
controls on day 59 (Fig. 5A). PLV-inoculated animals had a higher
proliferative response to both FIV and PLV on day 17, but this
difference did not achieve statistical signiﬁcance. Similarly, although
animals inoculated with FIV had a high proliferative response to both
FIV and PLV on study day 59, this difference did not achieve statistical
signiﬁcance.
CD4+ T-cell maintenance is associated with interferon gamma (IFN-γ)
expression
To determine if protection was associated with a strong TH-1 or
TH-2 cytokine response, cytokine mRNA (IL-10, IL-4, IL-12, TNF-α, and
IFN-γ) was measured using real time PCR from bulk PBMC. In order to
normalize for differences in measured cytokine expression between
sample days, cytokine levels are expressed as fold increase over values
at the same time point for controls. As shown in Fig. 6, cats inoculated
with PLV had a statistically signiﬁcant fold increase from controls in
IFN-γ expression on study days 10, 17, 31, 37, 52 and 59. FIV
inoculation was also followed by an increase in IFN-γ expression,
but not until day 52, (24 days after FIV inoculation). Nine of 10 PLV-
inoculated animals exhibited a 2-fold or greater (range=0.8–10.8,
mean=4) increase in IFN-γ between days 3 and 31. PLV-inoculated
animals thus had signiﬁcantly higher IFN-γ levels not only at the time
of FIV exposure, but for over 3 weeks following FIV inoculation.
Though samples were not available from all animals for analysis at day
108, the trend was for IFN-γ mRNA levels to return to baseline for all
infected groups (data not shown).
IL-10 (data not shown) was signiﬁcantly elevated on study day 52
in the FIV-inoculated animals. IL-4 expression (data not shown) was
slightly elevated in the groups receiving PLV from day 10 onward,
achieving statistical signiﬁcance on day 31. IL-4 was more variable in
the FIV-only group, falling below the control levels on day 52 andFig. 6. IFN-γ expression was measured by real time PCR. Level of expression relative to
that of the control group is shown as group means for groups inoculated with PLV or
medium only on day 0. Solid diamonds represent the PLV-inoculated group. Arrow
indicates inoculation of 5 animals from each group with FIV or diluent. Solid triangles
represent the single-virus inoculated group (FIV only) and shaded circles represent the
dual-virus inoculated (PLV followed by FIV) group. Asterisks indicate statistically
signiﬁcant differences (p≤0.05) from the control group. The number of samples tested
for each group at each time point was 10 (before day 28) or 5 (after day 28) with the
following exceptions: day 3 n=8 for control, day 10 n=9 for control, day 17 n=8 for
control, day 31 n=3 for control and n=4 for FIV.above on days 31 and 59, but not signiﬁcantly so. IL-12 expression
(data not shown) was not statistically different from control levels in
any group at any time point. TNF expression was also variable
demonstrating a statistically signiﬁcant difference only prior to and
day 10 after PLV inoculation.
PLV infection did not prevent neutropenia subsequent to infection with
FIV
Neutrophil counts declined precipitously in FIV-inoculated groups
with or without prior PLV inoculation (Fig. 7). Neutropenia was
signiﬁcant relative to baseline in PLV-infected, FIV-inoculated animals
on days 59 and 66 and in FIV-infected animals on days 66 and 80. The
diminished neutrophil count in these groups coincides with a
statistically signiﬁcant decrease in WBC count on days 59 and 66 for
the PLV/FIV group and on day 66 for the FIV-only group (data not
shown). The control group demonstrated a signiﬁcant neutrophilia on
day 45 while PLV-only animals experienced neutrophilia relative to
baseline on post-inoculation days 37 and 45.
Clinical signs were unremarkable
Mild lymphadenopathy was noted following PLV inoculation. FIV
inoculation resulted in mild to moderate lymphadenopathy in both
PLV-inoculated and sham-inoculated animals.
Discussion
Previous infection with a non-pathogenic lentivirus protected
against the signiﬁcant and prolonged peripheral blood CD4+ T-cell
depletion that occurs following inoculation with virulent FIV, con-
sistent with results of previous studies (VandeWoude et al., 2002).
Preservation of CD4+ lymphocytes did not correspond to an im-
mediate or sustained signiﬁcant decrease in peripheral viral load as
measured by viremia or intracellular (PBMC) virus and was not
dependent upon a high PBMC PLV viral load at the time of FIV
inoculation.
This disconnect between pathogenic viral load and CD4+ T-cell
depletion is consistent with results for the natural course of HIV
infection, in which it has been shown that CD4+ T-cell decline cannot
be predicted by viral load in untreated HIV infection (Rodŕiguez et al.,
2006); further, although infection with viral strains such as subtype
D results in a faster rate of CD4+ T-cell decline and more rapid pro-
gression of disease, set-point as well as early viral loads are equivalent
67J.A. TerWee et al. / Virology 377 (2008) 63–70to those in infection with less pathogenic strains (Baeten et al., 2007).
Similarly, in non-pathogenic SIV infection, consistently high viral
loads are not associated with peripheral blood CD4+ T-cell loss or
with the development of AIDS (Broussard et al., 2001; Chakrabarti,
2004; Rey-Cuille et al., 1998). Additionally, HIV-infected patients
undergoing treatment with anti-retroviral agents typically experience
a reduction of viral load to the limit of detection without complete
recovery of CD4+ T-cells (Goicoechea et al., 2006). Data from other
studies suggest a correlation between viral load and CD4+ T-cell loss
(Goldstein et al., 2005; Mellors et al., 1997), and undeniably viral
infection initiates the destruction of this cell population. It is therefore
evident that there are factors yet to be discovered to explain the
complex association of viral load with CD4+ T-Cell loss.
As might be predicted from our previous observations that PLV
does not induce a vigorous immune response during domestic cat
infection (TerWee et al., 2005), and that the homology between FIV
and PLV env is low (Smirnova et al., 2005), prevention of CD4+ cell
loss in this feline model was not linked to a cross-neutralizing
immune response to FIV in PLV-infected cats. An anamnestic virus
neutralizing antibody response was not observed after FIV inocula-
tion in the animals infected with PLV, and enhanced lymphocyte
proliferation to virus-speciﬁc antigen was not detected. Although
additional measures may reveal a role for adaptive immunity in the
mechanism of protection against lentivirus-induced immunodeﬁ-
ciency, our results are consistent with those reported in many HIV,
SIV and FIV studies that fail to show a clear cause-and-effect relation
between protection and a robust immune response (Amara et al.,
2005; Hosie et al., 1988; Langlois et al., 1998; Singh et al., 2005;
Stebbings et al., 2002). In a recent study, non-progressors and
patients treated with HAART actually had lower neutralizing anti-
body responses to autologous virus than untreated viremic patients,
indicating that the viral replication was driving the antibody
response rather than being controlled by it (Bailey et al., 2006).
This has also been documented in SIV; an antibody response was
detected after challenge exposure in non-vaccinated groups and in
vaccinated progressors, but not in the vaccinated and protected non-
progressors (Kawada et al., 2007). Others however have noted a
correlation between induction of a post-vaccinal neutralizing anti-
body response against the challenge strain and reduction in viral
replication (Quinnan et al., 2005), a correlation between antibody
avidity and rate of disease progression (Korthels Altes et al., 2006),
and greater loss of CD4+ T-cells and increased viral replication after
experimental B-cell depletion (Miller et al., 2007), indicating that an
antibody responsemay be effective if it reaches a certain threshold of
quality and quantity. In light of the envelope diversity of circulating
strains of HIV, the goal of many vaccine research programs is a
cytotoxic T-cell response (Davenport et al., 2007; McMichael, 2006).
Disparate results for the effectiveness of this type of immune
response are also evident. Although depletion of CD8+ T-cells follow-
ing SIV infection has been shown to cause an increase in virus
replication (Schmitz et al., 2005), vaccines which induce high levels
of CD8+ T-cells have not been able to prevent infection or disease and
CD4+ T-cell loss (McMichael, 2006). Even though there is an overall
reduction in chronic viral replication, CTL escape mutants emerge
(Loffredo et al., 2007; Mandl et al., 2007) and an effective response is
achieved too late (Davenport et al., 2007).
In contrast to the lack of correlation between adaptive immune
response induction by PLV and down-regulation of PLV or protection
against FIV challenge, we have documented changes in recombination
rates, genomic selection, and mutation rate in PLV genomes following
passage through domestic cats, notable at key residues in pol and
signiﬁed by G to A conversion (Poss et al., 2006; Poss et al., 2007). This
accumulated evidence strongly supports innate and intracellular anti-
retroviral defenses are enhanced in the face of PLV infection in
domestic cats—supporting these host defenses as primary mechan-
isms preventing pathogen infection of non-target species.Prevention of superinfection is documented as a means by which
lentiviruses increase ﬁdelity. HIV downregulates the expression of its
binding receptor, CD4, during its replicative cycle (Lama, 2003;
Lindwasser et al., 2007). Although we have observed reduced FIV
replication after PLV inoculation in vitro (VandeWoude et al., 2002),
PLV and FIV appear to use different receptors (Smirnova et al., 2005).
Additionally, since the number of PLV-infected cells was low at the
time of FIV inoculation a global antiviral state induced by PLV infection
seems a more likely explanation for our observations than a direct
block to superinfection. In this context the ‘non-adapted’ pathogen is
prevented from replication and/or successful infection because the
new host has molecular machinery able to interfere with the lentiviral
lifecycle. It is interesting to speculate that these non-speciﬁc innate
factors, activated during PLV infection because of host:pathogen
discordance, modify the host environment to partially cripple
subsequent virulent FIV infection. While we did not see an overall
signiﬁcant reduction in FIV viral load in circulation, it is possible that
the viruses being produced were less ﬁt due to residual intracellular
restriction mechanisms induced by PLV infection. Evaluation of FIV
genomes for evidence of hypermutation and recombination will
determine this possibility.
It is also plausible that replication of virulent FIV was abrogated at
key sites of early replication other than PBMCs. Although high levels of
FIV are found in bone marrow (Beebe et al., 1992; Dua et al., 1994;
S. Troth, unpublished data), we have previously shown that PLV
cannot be detected in samples of bone marrow harvested 6 months
after PLV inoculation; however, proviral is maintained in gastro-
intestinal tract and associated lymph nodes (TerWee et al., 2005). Lack
of co-localization of the two viruses in bone marrow may explain the
absence of protection from neutropenia in dual-virus infected
animals; further, it is possible that FIV replication in FIV-PLV dual-
infected cats is limited in sites such as the gastrointestinal tract due to
primary interference with PLV, or redistribution of FIV target cells,
preserving CD4+ T-cell populations that ultimately circulate periph-
erally. Quantitation of both PLV and FIV in lymphoid and gastro-
intestinal tissues during single and dual infection will provide
informative clues about mechanisms underlying CD4+ T-Cell loss in
FIV-infected animals.
IFN-γ expression was increased in PBMC by both pathogenic
and non-pathogenic virus exposure, however animals protected from
CD4+ T-cell lymphopenia had a higher level of IFN-γ mRNA prior to
exposure to virulent virus. The role of IFN-γ in protection from feline
or human AIDS is not clear. Vaccinationwith a DNAvaccine expressing
IFN-γ has been shown not to reduce viremia following exposure to FIV
(Gupta et al., 2007). However, effect on CD4+ T-Cell count was
not determined since this challenge virus did not induce measurable
CD4 +T-cell loss. In HIV-infected individuals, CD4+ T-cell decline was
not found to correlate with HIV-speciﬁc IFN-γ secretion (Peretz et al.,
2005) and interferon gamma is at higher levels in pathogenic cross-
species SIV infection than in non-pathogenic infection, indicating that
an activated immune system is prognostic of pathogenesis (Kornfeld
et al., 2005). Conversely, other studies support our results of an
association between IFN-γ and diminished pathogenesis. Vaccine-
induced antigen-speciﬁc IFN-γ secretion has been shown to correlate
with survival, protection and reduced viral loads following challenge
with SIV or SHIV (Abel et al., 2003; Boyer et al., 2006; Sun et al., 2006).
Given that others have observed induction of cytidine deaminase
by treatment with IFN-γ in vitro (Jost et al., 2007) it is possible that
the protection we observed in conjunction with increased IFN-γ is
related to synergy between innate pathways of altered cytokine ex-
pression and intracellular restriction in individuals exposed to certain
pathogens.
The feline model provides a well controlled system to examine
pathogenesis, protection and early effects of infection with viruses
which induce immunodeﬁciency. Prior infection with a minimally
pathogenic virus from a related species provided solid protection from
68 J.A. TerWee et al. / Virology 377 (2008) 63–70CD4+ T-cell loss. Our data lend support to the body of evidence that
decouples viral replication and peripheral blood CD4+ T-cell loss. Our
data also support the lack of either an antibody or cell mediated
immune response in the responsibility for maintenance of this
population of cells. Further studies dissecting potential mechanisms
for our observations will provide fundamental knowledge toward the
understanding of the pathogenesis of AIDS.
Materials and methods
Viral stocks
Table 1 describes the viral stocks used in this study. The MYA-1 cell
line is of domestic cat PBMC origin (Miyazawa et al., 1989). PLV was
isolated from a co-culture of puma and domestic cat PBMCs and was
expanded in MYA-1 cells. FIV-C was recovered from the retro-
pharyngeal lymph node of a cat inoculated with a molecularly cloned
FIV-C by culture with MYA-1 cells. Reverse transcriptase (RT) activity
of culture supernatants was monitored and virus was harvested by
slow speed (200–500 ×g) centrifugation using a Beckman GPR cen-
trifuge with a GH 37 rotor (Beckman Coulter, Fullerton, CA) to remove
cell debris at peak RT activity. The sham inoculum (medium) was
similarly prepared from culture supernatant of un-infected MYA-1
cells.
Animals
Twenty speciﬁc-pathogen-free (SPF) cats were obtained from a
breeding colony at Colorado State University. Animals were rando-
mized by litter and gender and were housed in groups of 5 in pens in
isolation rooms in an AAALAC-international accredited animal facility.
All procedures were approved by the CSU Institutional Animal Care
and Use Committee prior to initiation.
Study design
Blood samples were obtained by venipuncture of the jugular or
cephalic vein on study days −11, −4, 3, 10, 17, 24, 31, 37, 45, 52, 59, 66,
80, 94, and 108 (relative to PLV exposure). On Day 0, ten 14–22 week-
old cats were inoculated IV with 1 ml of PLV while the remaining
10 cats received culture supernatant from un-infected MYA-1 cells IV.
Twenty-eight days later, 5 of the PLV-inoculated animals and 5 of the
sham-inoculated controls received 1 ml of FIV stock which had been
diluted 1:100 in 0.9% NaCL solution IV and the remaining animals
were inoculated by the same route with 0.9% saline. Thus study
termination was 108 days post PLV inoculation and 80 days post FIV
challenge.
Clinical signs
Animals were observed for clinical signs at least daily throughout
the study. Lymph nodes were palpated at least weekly. Body weightsTable 1
Description of virus stocks
Stock TCID50/mla Days in cultureb Copies/mlc RT activityd
PLV-1695 104.7 12 5×106 5847
FIV-C 107.2 17 Not done 19628
a Titer calculated on MYA-1 cells.
b Days in culture for ﬁnal passage.
c Calculated by real time PCR.
d Calculated by micro-titer reverse transcriptase assay.were measured weekly from 4 weeks prior to until 12 weeks post PLV
exposure.
Viral copy number
A real time PCR standard curve was generated from serial
dilutions of feline PBMC from 1000 to 5×106 subjected to real time
PCR for the cellular house-keeping gene, Glyceraldehyde-3-Phos-
phate Dehydrogenase (GADPH) as described by Leutenegger et al.
(1999). Peripheral blood mononuclear cells (PBMC) from study
animals were puriﬁed from heparinized whole blood samples from
experimental animals using a Histopaque (Sigma, St. Louis, MO)
gradient according to the product insert. DNA was extracted from 1
million PBMCs using the Qiamp blood mini DNA kit (Qiagen,
Valencia, CA). DNA from each sample was eluted with 50–200 µl
of buffer and PLV in 5 µl of sample was quantitated in triplicate using
real time PCR with plasmid encoded PLV as a positive control.
Primers and probe were designed for the pol region of PLV 1695. This
assay has a less than 3% within and between sample variance and is
sensitive to a minimum of 10 copies. The difference in ampliﬁcation
efﬁciency for plasmid vs sample DNA was less than 1% (Sondgeroth
et al., 2005). Primers and probe for FIV-C gag (Pedersen et al., 2001)
were used to quantitate FIV in PBMCs and plasma. The sensitivity of
detection is a minimum of 5 copies. Due to substantial heterogeneity
between FIV-C and PLV 1695, primers and probes are speciﬁc for
each virus and do not cross-amplify (reported in results). DNA
samples were also subjected to GAPDH real time analysis and values
normalized to GAPDH standard curve to determine the number of
cell equivalents per DNA sample; proviral copy number per cell was
calculated on this basis.
To determine the number of viral copies in plasma, RNA in 140 µl of
EDTA anti-coagulated plasma was puriﬁed using the Qiamp Viral RNA
Mini Kit (Qiagen, Valencia, CA). Following treatment with DNase
(DNA-free, Ambion, Austin, TX), RNA was transcribed to DNA using
Superscript II (Invitrogen) and then was quantitated using real time
PCR. The standard curve was generated using dilutions of a viral stock
which was quantitiated against a DNA plasmid standard curve, diluted
in negative plasma and then extracted using the same procedure as
samples. All samples collected on a given study day were prepared
and tested together.
Cytokines
Cytokines were quantitated by real time PCR using the method of
Leutenegger et al. (1999). Five to tenmillion PBMCs (puriﬁed as above)
were dissolved in Trizol (Sigma, St. Louis, MO) at 10 million cells/ml.
cDNAwas reverse transcribed from RNA puriﬁed by extracted phenol:
chloroform extraction and ethanol precipitation. Cytokine expression
for IL-10, IL12p40 and interferon gamma (IFN-γ) was quantitated
relative to that of the gene, GAPDH using the formula 2−ΔCT, where
ΔCT represents the cycle at which threshold is reached for the GAPDH
is subtracted from the cycle at which threshold is reached for thePassage history In vivo infectivity
Puma PBMC co-cultivated with
domestic cat cells
1 ml infected 14/14 cats IV and 4/4 ON
Retropharyngeal lymph node from
cat inoculated with
molecular clone cultured with
domestic cat cells
1 ml of 1:100 dilution
infected 11/11 cats IV and 2/2 ON
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and tested together.
Hematology
Total white and red blood cell counts were measured using a
Coulter Z1 (Coulter, Miami, FL). Differential counts were performed
manually and the percentages of lymphocytes positive for CD4, CD8
and CD25 were determined by ﬂow cytometry using monoclonal
antibodies to feline CD4 and CD8 (Southern Biotech, Birmingham, AL).
Two to ﬁve×105 PBMCs were incubated for 20–60 min at room
temperature in monoclonal antibody at 5 μg/ml in ﬂow buffer (PBS
containing 2% FBS and 0.2% sodium azide). Cells were then washed
twice in ﬂow buffer, resuspended in 100 µl of ﬂuorescein-labeled
sheep anti-mouse IgG (Sigma, St. Louis, MO) at 10 µg/ml in ﬂow buffer
and incubated for 20–60 min at room temperature in the dark. Cells
were washed once in ﬂow buffer and then analyzed with a Coulter
EPICS XL MCL ﬂow cytometer (Beckman Coulter, Miami, FL). List mode
ﬁles were analyzed using FlowJo (Tree Star Inc., San Carlos, CA). Total
cell counts for each phenotype were calculated by multiplying the
total white blood cell count by the percentage of lymphocytes in the
sample as determined by the differential count and then by the
percentage of lymphocytes expressing that phenotype.
Virus-neutralizing antibody (VN)
VN titer was determined by adding a constant amount of virus to
serial two fold dilutions of plasma, starting at a 1:5 ﬁnal dilution.
Following a 90-minute incubation at 37 °C with 5% CO2, 100 µl of the
virus/plasma mixture was added in triplicate to MYA-1 cells seeded at
1×105 cells/well in 96 well plates. The virus inoculum was titrated in
triplicate using 10 fold serial dilutions. Virus was detected by reverse
transcriptase assay after 14 days incubation at 37 °C with 5% CO2 and
titers of virus inoculum and antibody were calculated using the
Spearman–Kärber method (Blake and O'Connell, 1993).
Lymphocyte blastogenesis assay
One-hundred thousand PBMCs were incubated in triplicate with
medium alone, 1 µg of PLV or FIV inactivated using AT-2 (Rossio et al.,
1998) and 1.5 µg of Concanavalin A (Con A). 3H at 1 μCi/well was then
added 3 (Con A days −4, 17, 37, 45 and 52, 94 and 108) or 4 (antigen,
PMA, and days 59 and 66 for Con A) days later and the cells were
harvested onto ﬁlter paper using a 96 well cell harvester (Wallac,
Turku, Finland) 20 h later. Stimulation indices were calculated by
dividing the count for each sample by the count with medium alone.
Statistical analysis
Repeated-measures analysis of variance (ANOVA) was used to
determine if signiﬁcant differences (pb0.05) could be attributed to
treatment or time. If a signiﬁcant difference was detected, individual
comparisons of groups or time points were conducted using the
Student t test or Student t test for paired data as appropriate. All
analyses were performed using Microsoft Excel (Microsoft Corpora-
tion, Redmond WA.)
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